See this page online at: http://www.biotechfocus.com/2010Issue3
 |
Sign up for your free subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
Survey Says: Funding Gap Widens as Biotech Remains Neglected in Canada
By Shawn Lawrence
With this, our fourth Hot Button Issue, Biotechnology Focus once again polled its readers from both industry and academia to list their personal top three priorities they’d like to get before government. What comes from their answers is a powerful tool highlighting the issues the sector faces going forward and what government needs to do to help the industry compete at the highest possible level. |
|
Access to Capital: Will be Defining for many Canadian Biotech Companies in 2010
By Peter Van Der Velden
For emerging private health and life sciences companies in Canada the defining issue in 2009 was access to capital and this will continue in 2010. |
|
Canadian Healthcare in 2009: Survival, Success, Surrender
By James Smith and Wayne Schnarr
Public Canadian healthcare companies operate in a complex, challenging and constantly changing global environment. In 2009, some companies celebrated success, while most focused on survival; unfortunately, a few of them did not make it. Considering the combination of increased financing, partnerships, share price increases and several positive clinical and regulatory events, 2009 was a good year for the sector. However, this positive performance was overshadowed by a few clinical failures that landed in the headlines, coupled with the lack of a defining positive event in the sector. There are a number of clinical and regulatory events expected in 2010 and a series of positive results could provide some upward momentum and renew investor interest in this sector. |
|
Major Scientific Facilities in Canada: Challenges and Solutions
T.I. Meyer, Head, Strategic Planning and Communications, TRIUMF, S.M. Taylor, President and CEO of Ocean Networks Canada
Canada’s portfolio of large-scale facilities for science and technology (S&T) plays a central role in advancing the country’s ability to participate and compete in the international league in critical S&T areas spanning the natural, life and health sciences. These major scientific facilities are research infrastructure platforms for both ‘big science’ and ‘small science’: They are the base for long-term research programs in ‘big science’ areas, including high energy and particle physics (e.g. TRIUMF, Sudbury Neutrino Observatory), astronomy (e.g. Canada-France-Hawaii Telescope), environmental sciences (e.g. NEPTUNE Canada, CCGS Amundsen), and genomics and proteomics (e.g. Structural Genomics Consortium). |
|
Ontario's Bioscience Industry CEOs: Speak Out About Affecting Their Ability to Grow in 2010 and Beyond
By Gail Garland
In the summer of 2009, the CEOs of Ontario’s SME bioscience companies came together at the open invitation of Ontario Bioscience Industry Organization (OBIO) for a meeting hosted in Gowlings Toronto boardroom. On the agenda was a discussion of the future of Ontario’s bioscience industry and its unprecedented lack of access to capital, a worsening situation threatening the sustainability of the industry. |
